Novartis
NEWS
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Magenta Therapeutics is teaming up with Ladenburg, Germany-based Heidelberg Pharma to improve curative bone marrow transplantation.
Novartis inked a collaboration deal with Pear Therapeutics to develop prescription digital therapeutics for schizophrenia and multiple sclerosis (MS).
Teva Pharmaceuticals will close its offices in Washington, D.C. and New York City as part of the cost-cutting measures.
Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration.
Here is a look at the life science companies viewed as the most innovative in the world.
Novartis may soon be looking to sell off its generics subsidiary Sandoz.
Teva and Mylan are looking over their shoulders this morning after the FDA gave Novartis and Momenta the green light for their Copaxone copycat drug.
Today STADA announced the appointment of Peter Goldschmidt as new CEO and chairman of the board.
JOBS
IN THE PRESS